Scalper1 News
Big pharma Bristol-Myers Squibb’s (BMY) new drug Opdivo scored another win Monday, as a late-stage trial in kidney cancer was stopped early because it had already hit its endpoint. Small biotech Exelixis (EXEL) also reported success in a kidney-cancer trial, driving its embattled stock up 50%. Bristol-Myers’ trial, called Checkmate-025, compared Opdivo with everolimus, better known as Novartis’ (NVS) Afinitor, in patients with advanced or Scalper1 News
Scalper1 News